RASopathic Skin Eruptions During Vemurafenib Therapy

March 2013 in “ PLoS ONE ”

Jeannine D. Rinderknecht, Simone M. Goldinger, Sima Rozati, Jivko Kamarashev, Katrin Kerl, Lars E. French, Reinhard Dummer, Benedetta Belloni

vemurafenib V600 mutant BRAF inhibitor photosensitivity maculopapular exanthema pruritus folliculitis alopecia keratosis pilaris acanthopapilloma plantar hyperkeratosis keratoacanthoma squamous cell carcinoma melanoma UVA protection skin reactions itching hair loss skin thickening skin cancer sun protection

Studysummary In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer ·

View this study on journals.plos.org →

Discuss this study in the Community →

Similar Research

5 / 1000+ results

research Correction: RASopathic Skin Eruptions during Vemurafenib Therapy

4 citations , October 2013 in “PLoS ONE”

This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.

research RASopathic alopecia: Hair changes associated with vemurafenib therapy

21 citations , March 2015 in “Journal of The American Academy of Dermatology”

In this study, five out of six patients treated with vemurafenib for metastatic melanoma experienced hair loss, which improved after topical steroid treatment.

research Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.

31 citations , March 2014 in “Journal of the European Academy of Dermatology and Venereology”

In this study, multiple cutaneous adverse effects were observed in patients with metastatic malignant melanoma receiving BRAF inhibitors, but most were well managed with appropriate treatment.

research Vemurafenib-induced pityriasis amiantacea: a case report

9 citations , October 2015 in “Cutaneous and ocular toxicology”

This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.

The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

6 citations , April 2013 in “Current Dermatology Reports”

This review discusses the cutaneous side effects associated with vemurafenib and ipilimumab in metastatic melanoma treatment and emphasizes the importance of dermatologists in managing these skin eruptions; it reports no new clinical results.